Dutch Bros to Post Q1 Earnings: What's in the Cards for the Stock?
BROS is set to report Q1 2026 on May 6, with EPS and revenues seen rising on same-shop gains and new…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
+36.1% vs SMA 50 · +110.5% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $141.4M $86.5M–$214.1M | — | -$0.52 | — | ±5% | High5 |
FY2026(current) | $9.1M $4.6M–$20.1M | ▼ -93.6% | -$1.12 | — | ±50% | High9 |
FY2027 | $76.0M $8.4M–$238.5M | ▲ +736.0% | -$1.18 | — | ±5% | High9 |
BROS is set to report Q1 2026 on May 6, with EPS and revenues seen rising on same-shop gains and new…

roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak